{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:22:46Z","timestamp":1789726966954,"version":"4.0.1"},"reference-count":83,"publisher":"JLE","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF14OC0013659"],"award-info":[{"award-number":["NNF14OC0013659"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.nephro.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T11:30:57Z","timestamp":1522323057000},"page":"S31-S37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"S1","title":["Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives"],"prefix":"10.1684","volume":"14","author":[{"given":"Peter","family":"Rossing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Frimodt-M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among us adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.nephro.2018.02.007_bib0010","first-page":"336","article-title":"The prognosis of insulin-dependent diabetes mellitus. An epidemiological approach","volume":"39","author":"Borch-Johnsen","year":"1989","journal-title":"DanMedBull"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.007_bib0015","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study","volume":"11","author":"de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.007_bib0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/BF00400995","article-title":"Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients","volume":"34","author":"Gall","year":"1991","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.nephro.2018.02.007_bib0025","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.nephro.2018.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990\u20132010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.007_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ki.2014.206","article-title":"Improved prognosis of diabetic nephropathy in type 1 diabetes","volume":"87","author":"Andr\u00e9sd\u00f2ttir","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0040","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2337\/dc13-2036","article-title":"Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors","volume":"37","author":"Andr\u00e9sd\u00f2ttir","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nephro.2018.02.007_bib0045","series-title":"Brenner and Rector: the kidney","first-page":"1411","article-title":"Diabetic nephropathy","author":"Parving","year":"2012"},{"issue":"Supplement 1","key":"10.1016\/j.nephro.2018.02.007_bib0050","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.2337\/dc17-S013","article-title":"Microvascular complications and foot care","volume":"40","author":"American Diabetes Association","year":"2017","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.nephro.2018.02.007_bib0055","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"issue":"7448","key":"10.1016\/j.nephro.2018.02.007_bib0060","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.38070.450891.FE","article-title":"Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study","volume":"328","author":"Hovind","year":"2004","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.007_bib0065","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2337\/dc11-1380","article-title":"Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study","volume":"35","author":"Solini","year":"2012","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.007_bib0075","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2337\/dc15-0641","article-title":"The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes","volume":"38","author":"Thorn","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.nephro.2018.02.007_bib0080","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.007_bib0085","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.02.007_bib0090","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.ki.5000377","article-title":"Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective","volume":"69","author":"Parving","year":"2006","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.nephro.2018.02.007_bib0095","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1681\/ASN.2010010063","article-title":"Comparison of different measures of urinary protein excretion for prediction of renal events","volume":"21","author":"Lambers Heerspink","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.007_bib0100","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.007_bib0110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/00365517609068016","article-title":"Selection of routine method for determination of glomerular filtration rate in adult patients","volume":"36","author":"Br\u00f6chner-Mortensen","year":"1976","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00125-005-0077-3","article-title":"Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005","volume":"49","author":"Rossing","year":"2006","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0120","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","article-title":"Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis","volume":"52","author":"Magee","year":"2009","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0125","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.007_bib0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2018.02.007_bib0135","series-title":"Brenner and Rector's the kidney","first-page":"1283","article-title":"Diabetic nephropathy","author":"Rossing","year":"2016"},{"key":"10.1016\/j.nephro.2018.02.007_bib0140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/diab.42.5.715","article-title":"Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients","volume":"42","author":"Rossing","year":"1993","journal-title":"Diabetes"},{"key":"10.1016\/j.nephro.2018.02.007_bib0145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/BF02374501","article-title":"The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy","volume":"36","author":"Gall","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.nephro.2018.02.007_bib0150","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1056\/NEJM199611283352203","article-title":"Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group","volume":"335","author":"Nelson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.007_bib0155","article-title":"Progression promoters and target blood pressure in type 1 diabetic patients with diabetic nephropathy","author":"Hovind","year":"91998","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.007_bib0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ki.2014.206","article-title":"Improved prognosis of diabetic nephropathy in type 1 diabetes","volume":"87","author":"Andr\u00e9sd\u00f2ttir","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.007_bib0165","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney International"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0170","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/j.1523-1755.2004.00925.x","article-title":"Progression of nephropathy in type 2 diabetic patients","volume":"66","author":"Rossing","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.007_bib0175","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJM198905043201801","article-title":"Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy","volume":"320","author":"Seaquist","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2337\/db08-1514","article-title":"Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes","volume":"58","author":"Pezzolesi","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.007_bib0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1681\/ASN.2016020231","article-title":"The genetic landscape of renal complications in type 1 diabetes","volume":"28","author":"Sandholm","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.02.007_bib0190","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/ki.1996.266","article-title":"Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy","volume":"49","author":"Parving","year":"1996","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.007_bib0195","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1523-1755.2005.00521.x","article-title":"Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study","volume":"68","author":"Astrup","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.02.007_bib0200","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.007_bib0205","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.007_bib0210","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"Gaede","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.nephro.2018.02.007_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1470320316652047","article-title":"Prevention of microalbuminuria using early intervention with renin\u2013angiotensin system inhibitors in patients with type 2 diabetes: a systematic review","volume":"17","author":"Persson","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"25","key":"10.1016\/j.nephro.2018.02.007_bib0220","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"DCCT\/EDIC Research Group","year":"2011","journal-title":"N Engl JMed"},{"issue":"15","key":"10.1016\/j.nephro.2018.02.007_bib0225","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.nephro.2018.02.007_bib0230","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.007_bib0235","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.02.007_bib0240","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.007_bib0245","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0250","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"8","key":"10.1016\/j.nephro.2018.02.007_bib0255","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/j.1464-5491.2012.03585.x","article-title":"Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study","volume":"29","author":"Nielsen","year":"2012","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0265","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0270","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0735-1097(02)81115-9","article-title":"Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction","volume":"39","author":"Epstein","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.007_bib0275","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0280","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin\u2013angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.007_bib0285","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.007_bib0290","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.007_bib0295","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: a randomized clinical trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.007_bib0300","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.nephro.2018.02.007_bib0305","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0310","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0315","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.nephro.2018.02.007_bib0320","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0325","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.nephro.2018.02.007_bib0335","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/dc12-1298","article-title":"Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy","volume":"36","author":"Araki","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0340","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/dc09-2242","article-title":"Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients","volume":"33","author":"Nielsen","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0345","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2337\/dc07-2469","article-title":"Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy","volume":"31","author":"Nguyen","year":"2008","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0350","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc07-1960","article-title":"Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate","volume":"31","author":"Astrup","year":"2008","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.nephro.2018.02.007_bib0355","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2018.02.007_bib0360","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?","volume":"3","author":"Stenvinkel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.007_bib0365","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.nephro.2018.02.007_bib0370","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.2337\/dc14-0225","article-title":"Added value of soluble tumor necrosis factor alpha receptor-1 as a biomarker of ESRD risk in patients with type 1 diabetes","volume":"37","author":"Forsblom","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.007_bib0375","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.nephro.2018.02.007_bib0380","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.kint.2016.10.046","article-title":"Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes","volume":"91","author":"Krolewski","year":"2017","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.nephro.2018.02.007_bib0385","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2362.2012.02674.x","article-title":"Implementation of proteomic biomarkers: making it work","volume":"42","author":"Mischak","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0390","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/ki.2015.199","article-title":"Biomarkers of rapid chronic kidney disease progression in type 2 diabetes","volume":"88","author":"Looker","year":"2015","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.nephro.2018.02.007_bib0395","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.2337\/db12-0348","article-title":"Urinary proteomics for early diagnosis in diabetic nephropathy","volume":"61","author":"Zurbig","year":"2012","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.nephro.2018.02.007_bib0400","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12265-012-9382-7","article-title":"Perspectives on systems biology applications in diabetic kidney disease","volume":"5","author":"Komorowsky","year":"2012","journal-title":"J Cardiovasc Transl Res"},{"issue":"1","key":"10.1016\/j.nephro.2018.02.007_bib0405","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12967-016-0960-3","article-title":"Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus","volume":"14","author":"Pena","year":"2016","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.nephro.2018.02.007_bib0410","doi-asserted-by":"crossref","first-page":"e010310","DOI":"10.1136\/bmjopen-2015-010310","article-title":"Proteomic prediction and renin\u2013angiotensin\u2013aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial","volume":"6","author":"Lindhardt","year":"2016","journal-title":"BMJ open"},{"key":"10.1016\/j.nephro.2018.02.007_bib0415","series-title":"Comprehensive clinical nephrology","article-title":"Clinical manifestations and natural history of diabetic nephropathy","author":"Vora","year":"2000"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518300221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.02.007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:12:36Z","timestamp":1741173156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518300221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":83,"alternative-id":["S1769725518300221"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.007","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}